Medivir is a drug discovery and development company focusing on transformative cancer drugs. Our research and development are based on our extensive expertise in protease inhibitor design and nucleoside/nucleotide science.
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects in various phases.Partnership >
New data from the phase I study of birinapant in combination with Keytruda® will be presented at the ASCO 2019Read more
Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meetingRead more
Resolutions at the Annual General Meeting in Medivir on 9 May 2019Read more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.